Instil Bio's subsidiary, SynBioTx, entered into a license and collaboration agreement with ImmuneOnco Biopharmaceuticals, granting exclusive rights to develop certain antibodies outside of China, with potential payments of up to $50 million upfront and up to $2.1 billion in milestones and royalties.